drugset / Trial / NCT05030545

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

NCT05030545

Phase 4 Recruiting 40 enrolled Brigham and Women's Hospital
NaSingle-groupOpen-labelTreatment

Summary

This research study aims to learn more about the impact the hormone aldosterone on the heart. Primary aldosteronism is a condition where the body's adrenal glands make too much of the hormone aldosterone, which can cause high blood pressure and increase the risk of heart and kidney disease. Treatment with medications that block aldosterone can reduce that risk. This study is trying to learn whether treatment with a medication that blocks aldosterone can improve heart function in people who make too much aldosterone.

Timeline

Start
2022-12-15
Primary completion
2026-10-31
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Eplerenone Unknown 100 mg